Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

A Pathway, Not A Shortcut: 505(b)(2) NDAs Have Longer Reviews Than NMEs

18 Mar 2017

• By Bridget Silverman

StacksOfPapers_1200x675

Related Content

Novel Approvals Were Fewer But Faster At US FDA In 2016

02 Jan 2017

Big Pharma's Winning Formula: Many Approvals, Narrow Markets

04 Jan 2016

Once More, With Statistics: FDA Defends Division Productivity Differences

31 Aug 2015

Additional Topics

Drug Review Drug Approval Standards Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.